Key Highlights
- Q4 earnings per share reached $0.11, surpassing projections by $0.60
- Quarterly revenue achieved $147M, significantly exceeding the $90.25M analyst consensus
- Company delivered $18M net profit versus an $81M deficit in the prior-year quarter
- 2026 adjusted revenue guidance elevated to $230M–$270M from previous $185M–$205M target
- Strategic partnerships, highlighted by a $530M Pfizer agreement for Matrix-M adjuvant technology, fuel positive momentum
Novavax (NVAX) delivered impressive fourth-quarter results that exceeded analyst expectations across key metrics while simultaneously enhancing its 2026 revenue projections.
The biotech firm achieved Q4 earnings per share of $0.11, substantially outperforming the analyst consensus of -$0.49 by $0.60. Quarterly revenue reached $147 million, representing a 67% increase from the year-ago period and significantly surpassing the consensus forecast of approximately $90 million.
The company recorded net income of $18 million for the quarter. This result marks a sharp contrast to the $81 million net loss reported during the comparable quarter last year, reflecting successful expense management and growing licensing income.
NVAX shares settled at $9.53 during the session. The stock has gained 35.18% during the trailing three-month period and posted a 34.99% advance over the past year.
InvestingPro assigns a “great performance” rating to Novavax’s Financial Health score.
Vaccine sales represented only part of the quarterly performance story. Strategic licensing arrangements have emerged as a central element of Novavax’s business model, contributing meaningfully to financial results.
During the previous month, Novavax reached an agreement to license its Matrix-M adjuvant technology to Pfizer in a deal valued at up to $530 million. Matrix-M serves as the immune-boosting component within the company’s Nuvaxovid vaccine.
CEO John Jacobs highlighted growing demand for the company’s proprietary technology. “We have more interest than I’ve ever seen in three years in our tech and some great conversations going on,” he shared with Reuters.
Enhanced 2026 Revenue Guidance
Novavax has updated its 2026 adjusted revenue expectations to a range of $230 million to $270 million. This represents an increase from the company’s earlier projection of $185 million to $205 million.
These projections do not incorporate sales and royalty streams from the Sanofi collaboration, which provide additional revenue potential beyond the updated guidance range.
Management anticipates that milestone payments stemming from vaccine supply contracts and licensing arrangements will help balance softer demand trends in the COVID-19 vaccine market.
Regulatory Environment Considerations
COVID-19 vaccination uptake has declined in the United States under the present administration, which has implemented vaccine policy changes affecting the entire sector.
Jacobs recognized the industry’s position. “We probably disagree as a scientific community and an industry with some of their positions,” he stated, while noting that they “do see a pathway forward.”
Earlier during the month, the FDA initially refused to accept Moderna’s mRNA influenza vaccine submission before reversing course after Moderna modified its application. Jacobs expressed encouragement, saying it was “good to see them have a regulatory path forward.”
Novavax aims to reach complete profitability by 2028, backed by important product launches emerging from its Sanofi collaboration. Among these is a combination COVID-flu vaccine incorporating the Nuvaxovid platform.
Analyst EPS estimates saw 0 upward revisions and 2 downward revisions during the 90-day period preceding the earnings announcement.
Quarterly revenue of $147 million exceeded the average analyst projection of $78.84 million, based on LSEG data.
